Registered title, quoted from ClinicalTrials.gov
An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06942143, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Negative pregnancy tests in women of childbearing potential prior to study treatment; Consent must be given to use effective contraception during treatment.
Inclusion criterion 24
Patients who received major surgery, conventional chemotherapy, large area radiotherapy, immunotherapy or biological therapy within 4 weeks before entering the trial;
Exclusion criterion 1
no recovery from previous surgery or treatment-related adverse events to ≤ grade 2 CTCAE;
Exclusion criterion 3
Administration of chronic systemic cortisone steroids, hydroxyurea, and immunomodulatory agents (e.g., interleukin-2, interferon-α or γ, GM-CSF, mTOR inhibitors, cyclosporine, thymosin, etc.) within 4 weeks prior to cell therapy."
Exclusion criterion 8
ECOG score 0-1;
Inclusion criterion 8
WBC ≥3.0×109/L;
Inclusion criterion 13
Absolute neutrophil count (ANC) ≥1.5×109/L;
Inclusion criterion 14
platelet (PLT) ≥75×109/L;
Inclusion criterion 16
hemoglobin ≥10g/dL (no blood transfusion in the past 7 days);
Inclusion criterion 17
24-hour creatinine clearance ≥60mL/ min;
Inclusion criterion 20
Aspartate aminotransferase (AST/SGOT) ≤2.5×ULN;
Inclusion criterion 21
alanine aminotransferase (ALT/SGPT) ≤2.5×ULN;
Inclusion criterion 22
Total bilirubin (TBIL) ≤1.5×ULN
Inclusion criterion 23
Measurable lesions according to RECIST1.1 criteria.
Inclusion criterion 4
Pregnant or lactating women;
Exclusion criterion 12
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06942143, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Sign informed consent before conducting any trial-related activities;
- Age of 18-75 years old, male or female;
- Patients with first-line treatment failure;
- Measurable lesions according to RECIST1.1 criteria.
- During the trial screening period, the following two screening criteria must be met (by the sponsor) :
- HLA-A*02 positive;
- The positive rate of NYESO-1 immunohistochemical staining was ≥20%.
- ECOG score 0-1;
- The expected survival time is more than 3 months;
- Antineoplastic drugs and treatments were not allowed for 4 weeks before TCR-T cell infusion;
- Echocardiography showed left ventricular ejection fraction ≥50%;
- Laboratory test results should at least meet the following specified indicators:
- WBC ≥3.0×109/L;
- Absolute neutrophil count (ANC) ≥1.5×109/L;
- Absolute lymphocyte count (ALC) ≥1.0×109/L;
- platelet (PLT) ≥75×109/L;
- hemoglobin ≥10g/dL (no blood transfusion in the past 7 days);
- Prothrombin time or INR≤1.5x upper limit of normal unless receiving anticoagulant therapy;
- Partial prothrombin time (APTT) ≤1.5x upper limit of normal time, unless receiving anticoagulant therapy;
- 24-hour creatinine clearance ≥60mL/ min;
- Aspartate aminotransferase (AST/SGOT) ≤2.5×ULN;
- alanine aminotransferase (ALT/SGPT) ≤2.5×ULN;
- Total bilirubin (TBIL) ≤1.5×ULN
- Negative pregnancy tests in women of childbearing potential prior to study treatment; Consent must be given to use effective contraception during treatment.
- During the whole period of the trial, I can regularly visit the enrolled research institutions for relevant testing, evaluation and management.
Exclusion Criteria:
- Patients who received major surgery, conventional chemotherapy, large area radiotherapy, immunotherapy or biological therapy within 4 weeks before entering the trial;
- Known to produce allergic reactions to any component of the trial treatment;
- no recovery from previous surgery or treatment-related adverse events to ≤ grade 2 CTCAE;
- Poorly controlled hypertension (systolic blood pressure > 160mmHg and/or diastolic blood pressure > 90mmHg) or clinically significant (e.g., active) cardio-cerebrovascular disease; Cerebrovascular accident (within 6 months before the signing of informed consent), myocardial infarction (within 6 months before the signing of informed consent), unstable angina, congestive heart failure of New York Heart Association class II or higher (Appendix), or severe arrhythmia that could not be controlled with medications or that had the potential to affect study treatment; Electrocardiogram (ECG) was significantly abnormal or the mean QTc interval was ≥450 msec on three consecutive occasions.
- Combined with other serious organic diseases and mental disorders;
- Have active systemic infection requiring treatment, including active tuberculosis, known HIV positivity, or clinically active hepatitis A, B, or C; (Virus carriers should be excluded)
- Patients with autoimmune diseases: those with a history of inflammatory bowel disease or a history of autoimmune diseases (such as systemic lupus erythematosus, vasculitis, and invasive lung disease) judged by the investigators to be not suitable for this study should be excluded; (Patients with vitiligo are not excluded).
- Administration of chronic systemic cortisone steroids, hydroxyurea, and immunomodulatory agents (e.g., interleukin-2, interferon-α or γ, GM-CSF, mTOR inhibitors, cyclosporine, thymosin, etc.) within 4 weeks prior to cell therapy."
- History of organ transplantation, autologous/allogeneic stem cell transplantation and renal replacement therapy;
- Known uncontrolled diabetes mellitus, pulmonary fibrosis, interstitial lung disease, acute lung disease or liver failure;
- Known alcohol and/or drug abuse;
- Pregnant or lactating women;
- Trial participants with any coexisting medical conditions or diseases judged by the investigators to be likely to impair the conduct of the trial;
- No legal capacity/limited capacity.
Quoted from ClinicalTrials.gov, NCT06942143, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06942143, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.